Sunshine Biopharma Closes $6M Offering at $0.55, Down from $0.6876 Announced
SBFM is trading near its 52-week low of $0.356 (4.7% above the low).
Summary
Sunshine Biopharma closed its public offering, raising approximately $6.0 million at $0.55 per unit, below the $0.6876 price announced on October 2. The offering sold 10,509,082 common units and 400,000 pre-funded units, each with one share and two Series D warrants exercisable at $0.66 for five years. If all warrants are exercised, the company could receive an additional $14.4 million. The lower final price and increased unit count reflect weak demand and add to the dilution pressure already flagged in recent filings. This follows the $4 million ATM program and the $7 million best-efforts offering announced earlier, compounding the company's financing needs. The stock trades near its 52-week low of $0.3564, and the reverse split approved in September remains a looming risk.
Updated with an SEC 424B4 filing · What changed
Updates
· SEC 424B4 — The 424B4 prospectus sets the offering at up to 10,509,082 common units and 400,000 pre-funded units, with Series D warrants exercisable at $0.66 for five years.
At the time of this announcement, SBFM was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.36 to $24.30. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.